An Open-Label Phase 4 Study of Carfilzomib Plus Dexamethsone to Assess Tolerability and Adherence in Subjects with Relapsed or Refractory Multiple Myeloma at US Oncology Centers

Type of Cancer
Multiple Myeloma

Site
Bethesda

Protocol Number
Amgen 20170596

To Learn More Call
(201)-510-0950